[Premium Alert] My "Two-Time" Winning NASDAQ Biotech Stock (Details Inside)

Breakout Alert: Tuesday January 17, 2023 Could FDA Approval Send This Tiny Biotech Soaring! I'm Bringing Back My Wildly Successful "Two-Time" Winning Biotech Stock New Premium Alert TC BioPharm Holdings (NASDAQ: TCBP) Clinical Stage Biotech Company Serving Cancer Therapies Hi 10XProTrader Member, Did you read up on your new premium alert for 1/18 trading session that I sent you you just a couple of hours ago? You do NOT want to miss out on this trade set up, I can assure you of that. I have brought back my wildly successful 2X winning biotech stock because I believe the potential for a third huge run up in price move could be right around the corner for you! I alerted (TCBP) on 11/21/22 at 4PM EST when the stock was approximately $5.00/share. Then shortly after on 1/4/2023 (TCBP) the stock practically doubled in price as it ran to approximately $9.50/share! Look Below At The Chart of TCBP - Could We See a Third Huge Gain Take Place? The largest drug delivery-related acquisition ($1.9 BIL) took place last year between Amgen (NASDAQ:AMGN) and Five Prime Therapeutics (NASDAQ:FPRX) to support the former's strategy for international expansion and add to its oncology portfolio. And take Juno Therapeutics as another example. Founded in Seattle in 2013 to develop immunotherapy drugs, the company was acquired in 2018 by Celgene, a Biotech giant, for a whopping $9 BIL! Did you know that the FDA's time to approve cancer drugs in the decade ending in 2018 was 48% shorter than it was for treatments in other therapeutic fields? Immunotherapies that show the potential to revolutionize Cancer treatment could be a top priority for the FDA. Could We See (NASDAQ: TCBP) Be The Next Prime Candidate for a Take Over? TCBP - 2023 is Firing on All Cylinders to be an Epic M&A Year in Biopharma Analysts are anticipating that large drug makers will have big piles of cash to deploy this year, which could lead to some major mergers and acquisitions. By the end of 2023 eighteen large-cap U.S. and European biopharmas will have more than $500 BIL in ca∙sh on hand. According to analysts, one of the ways the companies could use the money is to strike deals. Big companies could be looking at young players like TCBP for innovation! Did you know that the FDA's time to approve cancer drugs in the decade ending in 2018 was 48% shorter than it was for treatments in other therapeutic fields? Immunotherapies that show the potential to revolutionize Cancer treatment could be a top priority for the FDA. TC Biopharm (NASDAQ: TCBP), a company that has only recently debuted on the NASDAQ, is developing groundbreaking, pioneering, and disruptive therapies with unrivaled applicability to a wide range of cancers and infectious diseases! TCBP is the newest Biopharma name to join the NASDAQ and could soon see tremendous value, fast growth, and wild momentum kick in? Whether the market was up, down, or sideways, there has been a flurry of biopharma companies hitting the public equity markets as the search for coronavirus-related innovation in treatments and vaccines has led to increased public and investor interest in the industry. What if there was a revolutionary way to potentially kill tumor cells? A way that isn't getting nearly enough attention as it should... The biopharma space is a treasure hunt for investors who scope the markets for promising companies that may hold the future of cancer treatment in their hands. TCBP's therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach! What TCBP is doing could be a game-changer for cancer treatment moving forward... Unlike the alpha beta T cells commonly used in CAR-T immunotherapy, gamma delta T cells play a role in the innate immune response, which constitutes the first, faster line of defense of the immune system. [Human gamma delta T cells]( (GDT cells) have extraordinary properties, including the capacity for tumor cell killing. These cells have the potential to overcome many problems in cancer therapy, especially for tumors with no known treatment. GDT cells constantly monitor the body for signs of biological stress, such as cancerous or infected cells, and are one of the first lines of defense against disease. How do they do this? By detecting changes in the cells, mediated by a complex series of events, the effect of which is common across all cancers and infections. [Advantages of using GDT Cells as a Cell Therapy Vehicle:]( - They activate a wider immune response through antigen presentation and cytokine/chemokine release. - They are completely safe for healthy cells and will not kill them, even when introduced at very high numbers. - They are naturally cytotoxic via a number of different mechanisms. - They are primed to infiltrate tissue, seeking sites of cellular stress and are biologically equipped to enter, reside and survive in a hostile tumor environment. - The GDT cell receptor is not MHC-restricted. This means that if GDT cells from a donor are transferred to a patient, the GDT cells don’t recognize the patient’s body as foreign and don’t cause graft versus host disease (GvHD). This makes them ideal for allogeneic “off the shelf” therapies. - They can be gathered from healthy donors, expanded to very high numbers, banked and frozen, using our validated GMP methods, providing a readily available starting material for manufacturing multiple products. TCBP Growing Research Finds that GDT Cells are the Newest Friend in Cancer Treatment This review demonstrates the historical work on GDT cell therapies and the promise offered by combinations or modifying them with transgenes. A study published in Nature Medicine in 2015 revealed that the number of gamma delta T cells that infiltrate a tumor was the best predictor of a favorable outcome for the patient. An analysis of gene expression from 18,000 individual tumors from 39 different malignancies showed that GDT cells were the infiltrating immune cells most likely to be associated with positive outcomes. Researchers have shown that there are various types of GDT cells, all with slightly different properties. TCBP is fascinated by the power of all subtypes and is actively developing drugs based on the ethos of using the subtype that is best equipped to fight the particular disease. Recent Activity In The Gamma Delta Vertical Could Set Up TCBP to Sky-Rocket - Bristol Myers Squibb - Bristol-Meyers Squibb inks $190M deal with Century Therapeutics and announces $50B in planned acquisitions and stock buybacks over the next 3 years - Takeda - Takeda Acquires Gamma Delta Therapeutics (Q4 2021) & Adaptate (January 2022) - Blackstone - Blackstone invests $250M in Autolous Therapeutics (AUTL) - Adicet Bio - Adicet announces data in 4 patients (Raises $100M) - Bayer - Bayer announces concerted effort to move into next generation cell and gene therapies. Clinical Expertise with a Step-changing Approach TCBP broad platform technology allows the company to design specific therapies to treat a broad range of cancers and infectious diseases with "off the shelf” allogeneic gamma delta T cell (GDT) products. The company is the leader in developing gamma-delta T cell therapies and the FIRST company to conduct phase II/pivotal clinical studies in oncology. The company's lead candidate, TCB002, is in phase 1 for acute myeloid leukemia. TCBP is also developing a cell therapy for COVID-19! TCBP is conducting two clinical trials for its unmodified gamma-delta T cell product ImmuniStim - a phase II/III pivotal trial in treatment of acute myeloid leukemia and a Phase I trial in treatment of COVID-19 patients. ImmuniStim uses the company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. The company also maintains a robust pipeline for future indications in solid tumors and other aggressive viral infections as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns its manufacturing facility to maintain cost and product quality controls. The company's stepwise approach to clinical development has enabled TCBP to take a logical, safer, and more agile approach to their clinical trials! By starting with an autologous, unmodified gamma delta product, the company was able to establish safety prior to entering the clinic in 2018 with their unmodified allogeneic product. Now, TCBP's focus is on clinical development and refinement of products based on the ideal GDT vehicle with a proprietary genetic CAR-T arsenal to fight a range of cancers. Exciting Oppor∙tunities Exist for the Massive Cancer Market Cancer is a curse, undoubtedly, but it is also a growth market for investors. According to Precedence Research, the global cancer drug market size is expected to be worth around $272 BIL by 2030 from at $136.2 BIL in 2020, growing at a CAGR of 7.2% from 2021 to 2030. The American Cancer Society has found that over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. According to researchers at Penn State College of Medicine, in 2018 the top 15 types of cancer cost the U.S. more than $156 BIL. The National Cancer Institute projects that cancer-related medical costs will skyrocket to $246 BIL by the end of this decade. It is the increasing awareness regarding the availability of various new therapies to treat cancer that is fueling the demand for cancer drugs and treatments among global cancer patients. TCBP is the latest contender in the enormous biopharma space that includes giants like Bristol-Myers Squibb and Pfizer... The company's focus on ground-breaking T-cell therapy could quickly catapult it to the frontline. TCBP is on a mission to develop safer, less expensive treatments that could target more cancers and potentially save more lives! TCBP Has "7" Key Potential Breakout Catalysts That Provide A Very Bullish Outlook! - Platform technology – allogenic (off-the-shelf) cell therapy for oncology. - Phase 2b / 3 clinical trial Q3 in acute myeloid leukemia - AML (“OmnImmune”). - FDA Orphan Drug status for OmnImmune granted, anticipated commercial product by 2023. - GDT CAR-T solid tumor clinical trials planned 2023. - Robust Intellectual Property Protection. - Strong management team with combined 60+ years of cell therapy experience. - Successfully demonstrated ability to generate pharma partnerships. You need to add TCBP to the top of your watch list (first thing) Wednesday morning! I am urging all of our 10X members to add TCBP to the top of your watch list right now, and be ready Wednesday morning. Please make sure you pay close attention to my updates via email and sms that I will be sending you. Yours for grater gains, Kevin Vander 10XProTrader.com Investment Research © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. This communication is a paid advertisement. 10XProTrader.coms is owned and operated by 10XMedia LLC, which is a Florida based Limited Liability Company and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. To date we have been compensated a total ($70,000 USD) Seventy Thousand dollars USD cash via bank wire to publicly disseminate information about TCBP via digital communication. We have never received stock in TCBP, nor have we traded it. Please review the full disc∙laimer at [( for important information about this advertisement. © 2022 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.